Diligence memo · auto-generated · as of July 2, 2026
CELL SOURCE Ltd
CELL SOURCE Ltd looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
CELL SOURCE Ltd operates in Biotechnology, based in TEL AVIV.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
CELL SOURCE Ltd has raised $500K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $500K on 2013-12-09.
Most recent recorded round closed around 2013-12-09.
Valuation (modeled)modeled
Provath models CELL SOURCE Ltd at approximately $28M (range $267K–$313M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.74× the median modeled value of Pre-Seed Biotechnology companies in 2013–2015 (131 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 12.6 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 11% of Biotechnology peers (4291 compared).
Modeled value ranks above 34% of those peers.
Closest niche peers: Truminim, LLC, Direct Spinal Therapeutics, Inc., Imanis Life Sciences, LLC, Universal Biosensors Inc, One World Lab, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.